ImageneBio stock faces a wide analyst target gap

ImageneBio stock was last at USD 4.64 on Nasdaq on September 28, 2026 at 4:00 p.m. ET, while the company formerly known as Ikena Oncology continues to develop its OX40 antibody olevaprubart. The valuation gap is striking: MarketBeat reported an average 12-month target of USD 29.00 on September 15, 2026.

Analyst targets span USD 28 to USD 30

The USD 29.00 average target stands against the USD 4.64 Nasdaq price, implying a 525.00 percent premium to the latest quoted level. MarketBeat also reported that five firms rated the stock collectively as Hold, with two sell ratings, one hold, one buy and one strong buy.

H.C. Wainwright initiated coverage with a Buy rating and a USD 28.00 target on August 21, 2026, according to MarketBeat. The same report placed the 52-week range at USD 3.94 to USD 9.10, leaving the latest price 49.01 percent below the high.

Q2 loss beat the consensus estimate

ImageneBio reported diluted EPS of minus USD 0.63 for Q2 2026, compared with a consensus estimate of minus USD 0.90, a USD 0.27 beat, MarketBeat reported on September 15, 2026. The finance statement for the quarter ended June 30, 2026 also shows USD 94.7 million in cash and a net loss of USD 10.2 million.

Cash funds the clinical program

At its September 14, 2026 conference presentation, management said cash stood at USD 136.0 million and could fund operations through Q1 2028, according to Investing.com. Olevaprubart is being tested in a phase 2b study for moderate-to-severe atopic dermatitis, with additional development planned in alopecia areata.

Stock stays below its yearly high

ImageneBio had a market capitalization of USD 52.3 million as of September 28, 2026. The USD 4.64 Nasdaq quote was 17.77 percent above the 52-week low and 49.01 percent below the 52-week high, framing a market that still prices the clinical program well below the analyst target range.